Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
Explain that a retrospective study showed a benefit for bevacizumab in patients with recurrent ovarian cancer, similar to benefits seen in prior clinical trials.
Note that the greatest benefit from bevacizumab was seen in platinum-sensitive ovarian cancer and those receiving second- or third-line treatment in combination with chemotherapy.
0
comments
:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.